Literature DB >> 7675120

Development of tolerance to antinociceptive effects of an intrathecal morphine/clonidine combination in rats.

J L Plummer1, P L Cmielewski, S Tallents, P D Hall, J Odontiadis, G K Gourlay, H Owen.   

Abstract

Previous animal studies have shown the antinociceptive effects of intrathecal clonidine and intrathecal morphine to be synergistic. This study investigated the intrathecal administration of multiple doses of this drug combination to examine the rate of development of tolerance and to determine whether there was any toxic effect on the spinal cord. Rats with indwelling intrathecal catheters were given saline, morphine (2.5-7.5 micrograms), clonidine (17.5 micrograms), or clonidine (17.5 micrograms) plus morphine (1 microgram) intrathecally twice daily for 4 1/2 days (total of 9 doses). Hot plate and tail flick tests were conducted after the first, fifth and ninth doses. After the ninth dose animals were killed and their spinal cords were removed for histological examination. Tolerance developed to the antinociceptive effects of the drug combination, but at a slower rate than to morphine alone. No evidence of toxicity or injury to the spinal cord was observed other than changes which could be ascribed to the presence of the catheter.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7675120     DOI: 10.1007/bf00170161

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  25 in total

1.  A validation study of the WHO method for cancer pain relief.

Authors:  V Ventafridda; M Tamburini; A Caraceni; F De Conno; F Naldi
Journal:  Cancer       Date:  1987-02-15       Impact factor: 6.860

2.  Spinal analgesia with morphine and clonidine.

Authors:  L M Kitahata
Journal:  Anesth Analg       Date:  1989-03       Impact factor: 5.108

3.  Studies in animals should precede human use of spinally administered drugs.

Authors:  T L Yaksh; J G Collins
Journal:  Anesthesiology       Date:  1989-01       Impact factor: 7.892

4.  Chronic spinal infusion of dexmedetomidine, ST-91 and clonidine: spinal alpha 2 adrenoceptor subtypes and intrinsic activity.

Authors:  Y Takano; T L Yaksh
Journal:  J Pharmacol Exp Ther       Date:  1993-01       Impact factor: 4.030

5.  A study of the interaction between clonidine and morphine on analgesia and blood pressure during continuous intrathecal infusion in the rat.

Authors:  C W Loomis; B Milne; F W Cervenko
Journal:  Neuropharmacology       Date:  1988-02       Impact factor: 5.250

6.  Neuropathologic lesions and CSF morphine concentrations during chronic continuous intraspinal morphine infusion. A clinical and post-mortem study.

Authors:  Dennis W Coombs; Jonathan D Fratkin; Frederick A Meier; David W Nierenberg; Richard L Saunders
Journal:  Pain       Date:  1985-08       Impact factor: 6.961

7.  Mutual potentiation of antinociceptive effects of morphine and clonidine on motor and sensory responses in rat spinal cord.

Authors:  G L Wilcox; K H Carlsson; A Jochim; I Jurna
Journal:  Brain Res       Date:  1987-03-03       Impact factor: 3.252

8.  Neuropathologic findings after long-term intrathecal infusion of morphine and bupivacaine for pain treatment in cancer patients.

Authors:  M Sjöberg; P A Karlsson; C Nordborg; A Wallgren; P Nitescu; L Appelgren; L E Linder; I Curelaru
Journal:  Anesthesiology       Date:  1992-02       Impact factor: 7.892

9.  Evaluation of possible spinal neurotoxicity of clonidine.

Authors:  T E Gordh; S Ekman; A S Lagerstedt
Journal:  Ups J Med Sci       Date:  1984       Impact factor: 2.384

10.  Evaluation of the toxicity of subarachnoid clonidine, guanfacine, and a substance P-antagonist on rat spinal cord and nerve roots: light and electron microscopic observations after chronic intrathecal administration.

Authors:  T Gordh; C Post; Y Olsson
Journal:  Anesth Analg       Date:  1986-12       Impact factor: 5.108

View more
  1 in total

1.  Altered antinociceptive efficacy of tramadol over time in rats with painful peripheral neuropathy.

Authors:  Aldric Hama; Jacqueline Sagen
Journal:  Eur J Pharmacol       Date:  2006-12-01       Impact factor: 4.432

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.